Table 4.

Baseline demographic and disease characteristics of patients in the VISTA, IFM 99–06, and MM-015 trials

^aAge >75 years.

^bIncludes additional data presented at the American Society of Hematology 2009 annual meeting (Wang ST et al., abstract 1379) that was not published in San Miguel et al. [13].

Abbreviations: IFM, Intergroupe Francophone du Myelome; ISS, International Staging System; MM, multiple myeloma; MP, melphalan and prednisone; MPR-R, MP plus lenalidomide with lenalidomide maintenance; MPT, MP plus thalidomide; NR, not reported; VISTA, Velcade as Initial Standard Therapy in Multiple Myeloma; VMP, bortezomib plus MP.